title: [Locally recurrent case of gastric cancer with serosal invasion after four months of endoscopic submucosal dissection].
abstract: A 52-year-old woman underwent endoscopic submucosal dissection (ESD) for early gastric cancer at the lesser curvature. Microscopic examination revealed tub1, pSM1, ly0, v0, pHM0, and pVM0, which were considered to be relative resection. Four months later, upper gastrointestinal endoscopy showed local recurrence with suspected SM massive tumor infiltration. We performed a laparoscopic distal gastrectomy with lymph node dissection. Postoperative pathology showed tub2, pT4a (SE), pN2, ly0, v0, and fStage IIIb. This indicated that a few remnant cancer cells were stimulated by the local inflammation associated with ESD. ESD is less invasive than open surgery, but strict observation following curative resection is essential to rule out inflammation-mediated recurrence.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine, Japan.
authors.forename: Mamiko
authors.initials: M
authors.lastname: Takii
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Kuroda
authors.forename: Yuka
authors.initials: Y
authors.lastname: Asano
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Sakurai
authors.forename: Kazuya
authors.initials: K
authors.lastname: Muguruma
authors.forename: Naoshi
authors.initials: N
authors.lastname: Kubo
authors.forename: Hisashi
authors.initials: H
authors.lastname: Nagahara
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kimura
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Amano
authors.forename: Eiji
authors.initials: E
authors.lastname: Noda
authors.forename: Nobuya
authors.initials: N
authors.lastname: Yamada
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Maeda
authors.forename: Masaichi
authors.initials: M
authors.lastname: Ohira
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004338:Drug Combinations; D004724:Endoscopy; D005260:Female; D005753:Gastric Mucosa / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010094:Oxonic Acid / Q000627:therapeutic use; D012008:Recurrence; D012704:Serous Membrane / Q000473:pathology*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid